Fujifilm to develop large-scale cell culture manufacturing site in U.S.

By Nikita Chaurasia  | Date: 2021-01-08

Fujifilm to develop large-scale cell culture manufacturing site in U.S.

In a bid to proliferate its biopharmaceutical contract development and manufacturing business, Fujifilm Corporation is reportedly planning to invest around USD 2 billion (200 billion yen) towards the development of a large-scale cell culture manufacturing site in the United States.

A subsidiary of this Tokyo-based multinational conglomerate, FUJIFILM Diosynth Biotechnologies, which also has production facilities in Denmark, the United Kingdom, as well as the United States will operate the new facility, cited sources with relevant information.

The new manufacturing facility will reportedly offer large-scale cell culture production capabilities of bulk drug substances with 8 x 20,000L bioreactors, with a potential to grow and add 24 x 20,000L bioreactors as per the market demand. The facility will also offer automated assembly as well as packaging and labeling services. Sources confirmed that this new site is likely to begin operations by the spring of 2025.

According to the President of Fujifilm Corp. Kenji Sukeno, the fresh investments will allow the company to develop as well as manufacture new drugs which can cater to the unmet medical demands. He added that the company intends to promote human health while supporting the growth of the healthcare sector by employing its advanced technologies and facilities to offer a continuous supply of state-of-the-art biopharmaceuticals.

Meanwhile, Martin Meeson, CEO at FUJIFILM Diosynth Biotechnologies mentioned that the Japanese conglomerate will deploy its expertise in biopharmaceutical development as well as manufacturing for producing vaccines, gene therapies, recombinant proteins, and antibodies.

Fujifilm is focusing on expanding its end-to-end service offerings throughout its biopharmaceutical CDMO businesses, sources claimed. The company reportedly invested around USD 928 million in its Denmark site FUJIFILM Diosynth Biotechnologies' Hillerød, to boost its cell culture production capacities as well as to add commercial-scale drug manufacturing capabilities.

It is worth mentioning that Fujifilm intends to achieve a yearly revenue of USD 2 billion for its biopharmaceutical CDMO (contract development and manufacturing) business by March 2025. Reportedly, the company believes that the fresh investment will boost its bio CDMO business annual growth rate to 20%, exceeding market predictions.

Source Credits –

https://www.prnewswire.com/news-releases/fujifilm-to-invest-over-200-billion-yen-2-billion-usd-to-establish-new-large-scale-cell-culture-manufacturing-site-for-biopharmaceuticals-in-the-usa-301202418.html

About Author

Nikita Chaurasia     aeresearch.net

Nikita Chaurasia

An accomplished professional in the field of content development, playing with words comes naturally to Nikita Chaurasia. After completing her post-graduate MBA degree in Advertising and PR, Nikita worked across numerous content-driven verticals, undertaking diverse r...

Read More >>

More News By Nikita Chaurasia

L&T Technology Services partners with Qualcomm to amplify 5G adoption

L&T Technology Services partners with Qualcomm to amplify 5G adoption

By Nikita Chaurasia

L&T Technology Services Limited has recently announced that it is teaming up with Qualcomm Technologies, Inc., the world’s leading wireless technology innovator. With the latest collaboration, the firm plans to offer end-to-end solutions...

PNAS, Straive partner to deliver end-to-end content production services

PNAS, Straive partner to deliver end-to-end content production services

By Nikita Chaurasia

Renowned U.S.-based nonprofit and non-governmental organization, NAS (National Academy of Sciences), has reportedly collaborated with Straive, one of the leading technology-driven solutions providers for Content, EdTech, and Data. With this acquis...

Japan pushes innovations in 'deep tech' sector with solar cell technology

Japan pushes innovations in 'deep tech' sector with solar cell technology

By Nikita Chaurasia

Amid the most promising next-generation solar cell technology innovations, Enecoat Technologies, a provider of materials development services in Japan, is reportedly developing perovskite. Following its completion, the Kyoto-located start-up expec...

GIC to acquire majority shares in opulent Sani/Ikos properties

GIC to acquire majority shares in opulent Sani/Ikos properties

By Nikita Chaurasia

Singapore's sovereign wealth fund, GIC has agreed to pay around $2.2 billion to buy a majority stake in Sani/Ikos Group, a Mediterranean luxury resort operator, marking the largest transaction in the European resort market since the Covid-19 pand...

Excelra, Patcore partner to offer enhanced digital insights to customers

Excelra, Patcore partner to offer enhanced digital insights to customers

By Nikita Chaurasia

Excelra, a data and analytics solutions provider, has recently announced its partnership with Patcore, Inc., to provide better access to its analytics products and scientific data for customers in Japan. For the unversed, Excelra is one of the top...